Short on US30 US30 has broken out to the downside of an ascending wedge with the trendline going back to the start of November with bearish RSI divergence. Entry on break of support and target at next resistance level @ 36300, I will also keep an eye out for a fib retrace level @ 34200. Happy trading.
Nyse
Pfizer's Surprising Turnaround: A Resilient JourneyIn an unexpected twist, Pfizer ( NYSE:PFE ), the U.S. pharmaceutical giant, has defied market expectations by reporting a surprise quarterly profit. This surprising turnaround can be attributed to the resilient demand for COVID-related products, outperforming the company's own projections. The earnings report for the fourth quarter revealed adjusted earnings of 10 cents per share, a stark contrast to the anticipated loss of 22 cents per share by analysts.
Pandemic Fallout and Pfizer's Struggles:
Investors had been skeptical about Pfizer's ( NYSE:PFE ) prospects as pandemic concerns waned and substantial revenues from COVID vaccine and treatment sales dwindled. The company faced an additional setback with its experimental obesity drug, contributing to a further decline in its stock value. This downturn reached levels reminiscent of the pandemic sell-off in 2020, resulting in a staggering $100 billion loss in market capitalization in 2023.
Resilient COVID Product Demand:
The silver lining for Pfizer ( NYSE:PFE ) emerged from the sustained demand for its COVID products, namely the antiviral treatment Paxlovid and the widely-used COVID vaccine Comirnaty, developed in collaboration with German partner BioNTech. Despite a significant drop in revenue from $57 billion in 2022 to $12.5 billion in 2023, these products played a crucial role in Pfizer's unexpected profitability.
Strategic Initiatives for Recovery:
To counter the adverse market trends, Pfizer ( NYSE:PFE ) has embarked on a strategic journey aimed at regaining profitability. A $4 billion cost-cutting program and internal restructuring form the cornerstone of the company's recovery plan. With these measures in place, Pfizer ( NYSE:PFE ) is optimistic about driving revenue growth through its cancer treatments, particularly following the $43 billion acquisition of cancer drugmaker Seagen. Additionally, the introduction of a new RSV vaccine is poised to contribute to the company's resurgence.
Outlook and Future Projections:
Pfizer's ( NYSE:PFE ) bold move to cut costs and refocus on high-potential areas, such as cancer treatments and vaccine development, has instilled confidence among investors. The company's projections for 2023 include an expected $1 billion in Paxlovid sales and $11.5 billion in Comirnaty sales. This outlook, combined with a 1.9% rise in premarket trading, suggests that Pfizer's strategic initiatives are resonating positively with the market.
Conclusion:
Pfizer's ( NYSE:PFE ) unexpected quarterly profit signifies a notable turnaround for the pharmaceutical giant. The company's ability to adapt to changing market dynamics, capitalize on resilient product demand, and implement strategic measures for recovery underscores its resilience. As Pfizer ( NYSE:PFE ) charts a course toward profitability, investors and industry observers are keenly watching how the company's strategic initiatives will shape its future in a post-pandemic landscape.
Starbucks to 98 Plus After Earnings !!Financial Performance: In 2023, Starbucks’s revenue was $35.98 billion, an increase of 11.55% compared to the previous year’s $32.25 billion. Earnings were $4.12 billion, an increase of 25.69%2.
Analyst Forecast: According to 21 analysts, the average rating for SBUX stock is “Buy.” The 12-month stock price forecast is $114.35, which is an increase of 23.22% from the latest price2.
Dividend Yield: Starbucks has a dividend yield of 2.4569%1, which could be attractive to income-focused investors.
Growth Estimates: The growth estimate for the next 5 years (per annum) is 16.63%3
TP 98
TESLA BACK TO 208 AFTER FOMCGAP TO FILL
Technical Analysis: Bullish traders want to see Tesla receive a positive reaction to its earnings print and for the stock to surge up and regain support at the 200-day SMA1
Market Position: Tesla’s stock bulls have reclaimed key chart territory, fueling hopes that the 2023 uptrend has resumed
Innovation: Tesla is known for its ability to overcome odds and innovate, which has led to significant gains in the past
Apple Back to 182 Consolidation AreaApple Inc.
Explore
A Bearish Perspective on Apple Stock
Apple Inc., the tech giant known for its innovative products and services, has been a darling of Wall Street for many years. However, some analysts are turning bearish on the company’s stock. Here’s a closer look at why.
Underperformance in 2023
Despite gaining an impressive 49% in 2023, Apple’s stock was the worst-performing FAANG constituent of the year1. The company reported negative revenue growth in all four quarters of 2023, the first time since 2001 that the company’s revenues fell YoY for four straight quarters1.
Downgrades in 2024
The start of 2024 hasn’t been positive for Apple either, with three brokerages downgrading the stock within the first two weeks of the year1. Redburn, Piper Sandler, and Barclays have all downgraded the stock1. While Redburn and Piper Sandler now rate the stock as a “Hold” or equivalent, Barclays downgraded the stock to a “Sell” equivalent with a Street-low target price of $1601.
Concerns Over iPhone Sales
Some brokerages are turning bearish on Apple amid fears of an extended slowdown in iPhone sales1. Analysts are especially worried about the outlook for iPhone sales in China, which is the company’s third-biggest market behind the U.S. and Europe, and accounted for around 19% of its fiscal year 2023 revenues1. Apple is facing tough competition from domestic Chinese smartphone companies like Huawei and Xiaomi1.
Humana's Stock Plunges But shows Signs of a Reverse Trend
Humana Inc., ( NYSE:HUM ) the second-largest Medicare Advantage company in the U.S., has sent shockwaves through the health insurance sector by revising its earnings guidance for 2025 and projecting 2024 profits well below analysts' expectations. The stock plummeted as much as 15%, marking the most significant intraday drop since June. This unexpected development has ignited concerns about the profitability of private Medicare plans and their potential impact on seniors' healthcare costs.
The Medicare Advantage Dilemma:
Humana's grim outlook stems from challenges faced by private Medicare plans, which have been a significant source of growth for health insurers in recent years. Rising medical costs are forcing Humana ( NYSE:HUM ) to consider raising prices and reducing benefits to maintain profit margins. Executives revealed on a conference call that this move may trigger a broader industry repricing of plans in the upcoming year, potentially signaling the end of the Medicare Advantage boom.
Industry-Wide Ripple Effect:
Humana's forecast has not only impacted its own stock but has also led to a sector-wide sell-off. Competitors such as UnitedHealth Group Inc., Cigna Group, CVS Health Corp., and Centene Corp. experienced substantial declines in their stock prices. The reasons behind the surge in medical costs vary among insurers, adding uncertainty to the already turbulent sector.
Regulatory Changes and Emerging Trends:
Several factors contribute to the challenging landscape for health insurers. The U.S. government's proposed changes to payment rates and plans to recoup past overpayments are colliding with an increase in medical costs as patients resume deferred care from the pandemic. These changes are being phased in over the next three years, creating additional pressure on insurers.
Humana's Long-Term Prospects:
The revised earnings guidance suggests a significant setback for Humana, as the projected adjusted earnings for 2024 are expected to be around $16 per share, a level not seen since 2018. Analysts express surprise and skepticism about the company's growth plans, with some doubting the feasibility of achieving a $6 to $10 per share growth in 2025.
Market Reaction and Investor Concerns:
Humana's dismal performance has ignited concerns among investors about the broader health insurance industry. Analysts are questioning whether the company can return to its long-term multiple and express concerns about slowing demographic trends in the 65+ market, which are expected to moderate in the second half of the 2020s.
Conclusion:
Humana's unexpected downturn serves as a stark reminder of the challenges facing health insurers, particularly those heavily invested in Medicare Advantage plans. The industry is at a crossroads, navigating regulatory changes, surging medical costs, and an uncertain economic landscape. Investors will be closely watching how competitors respond to these challenges and whether the Medicare Advantage boom is indeed coming to an end.
Ginkgo Bioworks (DNA) should test Resistance line at 1.55Daily chart, the stock rebounded from the support line S, and should target the falling Resistance line R at around 2.55
Crossing resistance and trading above 2.55 for 2 days, the target will be 2.30 extending to 2.47
Technical indicator RSI is in the BUY area.
LCID analysis ⏰ let's discuss :-: Hello 👋 it's me your RAJ 🙂 professional trader ✨
This idea 💡
is completely my own analysis to explain situation _&_ market conditions of NASDAQ:LCID
How this chart valid for long term 📌 explained clearly based on technical #TA 📌 #DYOR
::-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-::
Frankly speaking 🗣️ I am full time trader in Crypto 🔮 part time in stocks to save my money 💰
Based on my friend request , i am doing 📌 analysis ⏰ based on technical analysis #TA
I don't know it's fundamental and some other things to measure this as potential or bad stock based on technical i will talk 🦜
If u have experience and good knowledge in stock market especially usstock
Pls let me know about this company NASDAQ:LCID it helps me to check price in other conditions
:-) let's go 👀
In my opinion || chart 📉📈 looking too bad // continues downfall
Best area enter is ::👉 $2.6 - $4.1 👈
Best area to exit 🎯 :: $5.3 - $10.4 - $17 - $34
Stop 🛑 when price goes below $2.5 weekend candle close below Invalid 📌 to invest
Don't use 100% liquid 💰 it's high risk , so prefer 5-10% liquid 💰 on ur portfolio
Let me know points to consider on this stock , so i work and i will submit u those
👀 I always do analysis on crypto stocks _&_ large cap // rest of things i don't know much
__________________________________________________________________________________________
🪩 disclaimer :
▶️ TQ u for supporting 💚 follow idea 💡 get updates everytime ⏰ when I updated 📌
Note 👀
👉 keeping comments , reacting with emojis , pointing us is very easy to some people
They think 💬 what they see 📌 that was knowledge 📌
We need to learn market in many ways and should get adopted with experience, TECHNICAL ANALYSIS won't help understanding market structure and understanding bull 🐂 and bear 🐻 is more important
Economical conditions
Fundamentals
Technical
News
Sentiments
Checking macro to micro having good plan and build it is very important ☺️
Some Times market easily turn suddenly bear // bull 🤣 even we need to catch 🫴 those movements is also very important ☺️ 💛
I hope i cleared my view 🙂 if any points if I miss I will add in update 📌 post
Try to understand, try to learn - try to move with flexibility with market is important
Have good day 😊
TKO Group HoldingsI'm making this just for kicks.
Fundamentals:
Netflix (NFLX) and TKO Group Holding's WWE announced new partnership early Tuesday that will bring WWE's flagship program Raw to the streaming service, beginning January 2025.
TKO's agreement with Netflix has an initial 10-year term for an aggregate rights fee in excess of $5 billion.
Dwayne 'The Rock' Johnson is joining the WWE & UFC parent company's board of directors.
Technicals:
I have a bullish D.B. with this asset. The weekly TF out of the four is bearish, and that can solely be due to price breaking through a key monthly high, which in turn would start the retracement, but not all the time tho!
I would like to see a deeper correction before price actually start to take off, and this current bull movement it's showing looks to be a small pullback before the bears reenter the market in order to push price further down.
We all shall see...
ITW Bull flag formationReasons for bullish bias:
- Price forming a potential bull flag
- Entry is at breakout of pole for further confirmation
- HH breakout will also add confluence
- TP till projection
Entry Level (Buy Stop): 264.22
Stop Loss Level: 249.49
Take Profit Level 1: 278.95
Take Profit Level 2: 293.68
Take Profit Level 3: 300.56
Oracle's Ambitious Expansion in the Middle East
In a strategic move to capitalize on the Middle East's digital transformation, Oracle ( NYSE:ORCL ) is set to expand its operations in Dubai and build additional cloud infrastructure across the region. The company's Dubai office is undergoing a significant renovation, promising customers an immersive experience in envisioning the future of their companies through cutting-edge AI and cloud technology.
Strategic Investment for a Cloud-Powered Tomorrow
Amid a rising trend channel, Oracle's ( NYSE:ORCL ) stock outlook appears promising, reflecting investor confidence in the company's growth. With plans to invest in a state-of-the-art customer experience center in Dubai, Oracle ( NYSE:ORCL ) aims to offer a futuristic workspace and enable clients to visualize the potential of AI and cloud technology for their businesses.
Cloud Providers Tapping into the Middle East's Potential
Oracle's expansion aligns with the broader trend of global cloud providers establishing a significant presence in the Middle East, particularly in Saudi Arabia and the UAE. Companies like Microsoft, Amazon, IBM, and Alibaba Cloud have already opened cloud and data centers in the region, recognizing the growth potential fueled by a tech-savvy population and government-led digital initiatives.
Oracle ( NYSE:ORCL ), currently managing 67 cloud regions across 26 countries, underscores the Middle East's importance in its global strategy. Clay Magouyrk, Executive Vice President for Oracle Cloud Infrastructure, acknowledges the transformation of the Emirates into a global economic and technology powerhouse, driven by the widespread adoption of cloud services.
Empowering Women in Tech with sAIdaty Initiative
In a move to contribute to the UAE's digital economy goals, Oracle ( NYSE:ORCL ) has partnered with the Dubai Business Women Council to launch the sAIdaty initiative. This year-long program aims to enhance AI skills among women professionals and entrepreneurs. By equipping 500 council members with essential skills, the initiative not only advances women's professional journeys but also aligns with Oracle's commitment to fostering diversity and inclusivity in the tech sector.
Generative AI Integration - A Game-Changer for Enterprise Adoption
Oracle's focus on solving real-world business use cases is evident in its announcement of the general availability of the Oracle Cloud Infrastructure (OCI) Generative AI service. This fully managed service integrates large language models to address diverse business use cases, now supporting over 100 languages. The service's multilingual capabilities, improved GPU cluster management, and flexible fine-tuning options position Oracle as a leader in driving enterprise AI adoption at scale.
Conclusion: Oracle's Cloud-Powered Vision for the Middle East
As Oracle ( NYSE:ORCL ) expands its operations in Dubai and strengthens its cloud infrastructure across the Middle East, the company is not just responding to regional demand but actively shaping the digital future of the area. The combination of technical prowess, strategic partnerships, and a commitment to diversity positions Oracle as a key player in the region's evolving technological landscape. With the integration of generative AI, Oracle ( NYSE:ORCL ) is not only staying ahead of the curve but is also providing businesses with the tools they need to thrive in the era of digital transformation.
CANO While Cano Health Inc may be facing challenges, it's crucial to focus on the potential for recovery and growth. Use setbacks as stepping stones to success. The future holds opportunities for Cano Health to adapt and thrive in the ever-evolving healthcare landscape. Consider the current stock price under $3 as a potential entry point, but always conduct thorough research before making investment decisions. Remember, in adversity lies the opportunity for transformation and success. Keep a positive mindset and stay informed about the company's strategic initiatives for a brighter future.
Vardhman Acrylics Ltd :-: analysis ⏰ VARDHACRLC📌 DYOR ( do your own research 🔎 ) 📍 NFA
Above yellow 🟡 close 📌 beginning of upward ⬆️ momentum
It's small cap stock with high :-: promoters / with good dividend 📌
₹92 is key resistance 📌 we see some pressure :-: above it ☑️ never visit box below yellow 🟡
🎯 ₹111
🎯 ₹144
🎯 ₹300
Below green 💚 box 📍 danger ⚡
Just save my idea 💡 follow and give boosting 🚀 and pls share 🤝
Follow upcoming updates ..... 🧵 👇
ATAI looking to bottom out
After closely monitoring psychedelic stocks for approximately six months, my attention has been drawn to ATAI. Despite enduring a challenging period over the past couple of years, the stock appears to be signaling a potential turnaround.
Volume Analysis
A notable observation is the diminishing volume during each downturn, coupled with a substantial surge in volume in November of the previous year. This pattern indicates a decisive breakout from the prevailing trend.
RSI Insights
Simultaneously, the Relative Strength Index (RSI) reached its peak at 69. This represents the highest momentum level in the stock's history, signaling increasing strength. This noteworthy event marks the first instance of the weekly RSI surpassing the halfway mark, hinting at the initiation of a potential uptrend. Further supporting this indication is the presence of a bullish RSI divergence.
Anticipated Developments
My focus is straightforward, with two key criteria:
Demand Zone Confirmation ($1.05 - $1.29)
Previous High Breakout ($2.23)
The occurrence of these events could pave the way for significant upside potential in ATAI, as well as the entire psychedelic industry, with target projections reaching into the double figures.
An In-Depth Analysis of Cars.com (NYSE:CARS) Post Q3 EarningsCars.com (NYSE: NYSE:CARS ) has emerged as a digital hub connecting new and used car buyers and sellers. As we delve into the aftermath of the Q3 earnings report, it becomes clear that Cars.com is at a crossroads, navigating challenges but also seizing strategic opportunities for future growth.
Marketplace Resilience Amid Q3 Slowdown:
The broader online marketplace sector faced headwinds in Q3, with revenues beating analyst estimates by a modest 1.8%, while next quarter's revenue guidance lagged by 1.7%. However, Cars.com demonstrated resilience in the face of this trend. Despite a weaker quarter, the company's share prices rose by 4.6% on average since the previous earnings results, outperforming other cash-burning entities.
Q3 Performance and Strategic Moves:
Cars.com reported Q3 revenues of $174.3 million, a 5.9% YoY increase, in line with analyst expectations. The quarter, however, witnessed a decline in the user base and slow revenue growth. Despite these challenges, the company made strategic moves to fortify its position in the market. Notably, the launch of Cars Commerce, a new B2B brand, reflects a commitment to simplifying the car buying and selling process for all stakeholders. CEO Alex Vetter emphasized the strategic importance of this move, stating, "During the quarter, we made strong strategic moves that advanced our platform strategy and unlocked future growth."
Acquisition and Geographic Expansion:
Cars.com's acquisition of D2C Media Inc. is a noteworthy development, extending its presence in the Canadian market and unlocking new growth opportunities. This move aligns with the company's broader strategy of uniting the industry and fostering a seamless experience for consumers, dealers, OEMs, and lenders.
User Base Dynamics:
The Q3 report indicated a decline in the user base, with 18.7 thousand active buyers, down 4.44% YoY. While this is a notable setback, the company's focus on strategic initiatives and the launch of Cars Commerce could potentially reverse this trend in the coming quarters.
Future Outlook:
As the stock currently trades at $17.17, reflecting a 15.88% increase since the results, investors are cautiously optimistic. The success of Cars.com in the coming quarters will depend on its ability to capitalize on the launched initiatives, navigate challenges in the online marketplace sector, and harness the potential unlocked by the acquisition of D2C Media Inc.
Conclusion:
Cars.com ( NYSE:CARS ) stands at a pivotal juncture, having weathered the storms of a challenging Q3 while strategically positioning itself for future growth. The launch of Cars Commerce, the acquisition of D2C Media Inc., and the commitment to industry unification underscore a resilient strategy. Investors will be closely watching how Cars.com steers through the road ahead, making this digital marketplace a compelling stock to watch in the coming months.